An interventional study of Immunomodulating oral supplementation and Sip feed control in Head and Neck Squamous Cell Carcinoma, sponsored by Institut du Cancer de Montpellier - Val d'Aurelle. Terminated at 2 sites in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Institut du Cancer de Montpellier - Val d'Aurelle · Not applicable, Interventional, and Treatment
A change in patient care. Competing trials with the expansion of immunotherapies, Difficulties in manufacturing and obtaining products for double-blind studies. The health situation, with an temporary halt due to COVID-19.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 215 studies in Squamous Cell Carcinoma of Head and Neck with a site in France — 46 open to participants now, 80 under way, 20 of them phase 3. Squamous Cell Carcinoma of Head and Neck · France.
Among the 215 studies in Squamous Cell Carcinoma of Head and Neck with a site in France, this one is the 174th largest by enrollment of the 197 interventional ones that give a count, is one of 12 that started in 2019, is one of 32 with no phase, and was the 112th registered.
2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.
Browse Squamous Cell Carcinoma of Head and Neck studies →46 of the 215 studies in Squamous Cell Carcinoma of Head and Neck with a site in France are open now. Recruiting first, the newest first:
Corbus Pharmaceuticals Inc. · Sites in France, United States, Austria and 11 more countries
Ages 18+
Groupe Oncologie Radiotherapie Tete et Cou · Sites in France
Ages 18–80
Regeneron Pharmaceuticals · Sites in France, United States, Australia and 3 more countries
Ages 18+
University Hospital, Brest · Sites in France
Ages 18+
Groupe Oncologie Radiotherapie Tete et Cou · Sites in France
Ages 18–75
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
215 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 62 · Phase 2 86 · Phase 3 49
First in 1994; this study’s year is marked. 12 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 48 across 1,657 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.
Median enrollment 131 across the 197 interventional studies, 140 across the 17 observational. Of the 127 that completed or were terminated, 43 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
112 of 215 have an industry lead sponsor. The 10 most frequent:
Institut du Cancer de Montpellier - Val d'Aurelle is the lead sponsor of 142 studies on the registry; 46 are open to participants now.
Institut du Cancer de Montpellier - Val d'Aurelle has 3 studies filed under Squamous Cell Carcinoma of Head and Neck — fewer than ten, so there is no comparison to draw.
18 of the studies in Squamous Cell Carcinoma of Head and Neck with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03576417Phase 3Groupe Oncologie Radiotherapie Tete et CouA Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck | 2027-08 |
| NCT06064877Phase 3AVEO Pharmaceuticals, Inc.A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma | 2027-08 |
| NCT05094336AmgenA Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) | 2026-11-30 |
| NCT03070366Groupe Oncologie Radiotherapie Tete et CouStereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC | 2026-12 |
| NCT07151040One-carbon Therapeutics ABPhase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors | 2026-12 |
Add all 18 to your calendar (.ics) → With an account.
Among the 215 studies in Squamous Cell Carcinoma of Head and Neck with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators designed a prospective randomized double-blind trial to determine if the oral immunomodulating formula could improve the disease-free survival rate in high-risk locally-advanced head and neck Squamous Cell Carcinoma patients treated with Chemoradiotherapy.
The primary objective is to evaluate the efficacy on disease-free survival of a formula enriched with L-arginine, omega-3 fatty acids, and ribonucleic acids, taken for 5 days before each cycle of chemotherapy, in patients with high-risk locally-advanced HNSCC treated with postoperative concomitant chemoradiotherapy (CRT).
This study is a national, multicentric double blinded, randomised phase III trial. A total of 306 patients (102 patients in group control vs 204 patients in group Oral Impact®) will be required including 10% of lost-to-follow-up patients.
An immunomodulating oral supplementation compound (Oral Impact®) is compared to an isocaloric isonitrogenous control. The compound to be assessed contains 334kcal/bag and 18.1g of proteins, as well as immunomodulatory nutrients such as L-Arginine, RNA and omega-3. The control has the same formula to that of the Oral Impact®, but not enriched with specific nutrients. Each patient has to take Oral Impact® or a sip feed control during 5 days before each cycle of chemotherapy.
DFS will be measured from the time of randomization to the time of the first evidence of progression (local, regional, metastatic, or second primary) or death from any cause. Patients alive without carcinologic event were censored at last follow-up date.
Patients treated with postoperative CRT are expected to have a 2-year DFS rate of 60% without specific diet (pControl).
Including a ratio 1:2, an expected recruitment of 90 patients per year, the current study will require 131 events to detect an absolute improvement of 15% (HR=0.56, pExperimental=75%) with 0.90 statistical power using a two-sided test and a significance level of 0.05.
A total of 306 patients (102 vs 204) will be required including 10% of lost of follow-up patients.
The inclusion period would be 4 years, for an expected total duration of study about 8 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The immunomodulating oral supplementation compound (Oral Impact®) contains 334kcal/bag and 18.1g of proteins, as well as immunomodulatory nutrients such as L-Arginine, RNA and omega-3. Each bag of product containing powder (74g/bag) will be diluted in 250 millilitres of water by the patients and drunk at home. Three doses will be drunk at home by the patients daily, during the 5 days before each chemotherapy cycle.
Dietary Supplement: Immunomodulating oral supplementation
The control has the same formula to that of the Oral Impact®, but not enriched with specific nutrients: it is an isocaloric isonitrogenous control. Each bag of product containing powder (74g/bag) will be diluted in 250 millilitres of water by the patients and drunk at home. Three doses will be drunk at home by the patients daily, during the 5 days before each chemotherapy cycle.
Dietary Supplement: Sip feed control
Per os administration, 3 times / day, 5 days before each cycle of chemotherapy.
Per os administration, 3 times / day, 5 days before each cycle of chemotherapy.
Disease-Free Survival (DFS)
2-years DFS rate
Time frame: From date of randomization until the date of the first documented progression (local, regional, metastatic) or date of death from any cause, whichever came first, assessed up to 2 years.
Overall Survival (OS)
OS at 1, 2 and 3 years
Time frame: From date of randomization until the date of death from any cause, assessed up to 3 years.
Rate of drug compliance
the compliance is defined as the taking of more than 75 % of study product prescription
Time frame: up to 45 days
Adverse events rate
graded based on NCI-CTCAE v4.03
Time frame: until 3 months after radiotherapy
Quality of life by using the general quality of life questionnaire about cancer (QLQ-C30).
The EORTC QLQ-C30 uses for the questions 1 to 28 a 4-point scale. The scale scores from 1 to 4: 1 ("Not at all"), 2 ("A little"), 3 ("Quite a bit") and 4 ("Very much"). Half points are not allowed. The range is 3. For the raw score, less points are considered to have a better outcome. The EORTC QLQ-C30 uses for the questions 29 and 30 a 7-points scale. The scale scores from 1 to 7: 1 ("very poor") to 7 ("excellent"). Half points are not allowed. The range is 6. First of all, raw score has to be calculated with mean values. Afterwards linear transformation is performed to be comparable. More points are considered to have a better outcome.
Time frame: Quality of life will be assessed up to 2 years after the last day of radiotherapy.
Quality of life by using the specific quality of life questionnaire about head and neck cancer (HN35)
The EORTC HN35 uses a 4-point scale. The scale scores from 1 to 4: 1 ("Not at all"), 2 ("A little"), 3 ("Quite a bit") and 4 ("Very much"). Half points are not allowed. The range is 3. For the raw score, less points are considered to have a better outcome.
Time frame: Quality of life will be assessed up to 2 years after the last day of radiotherapy.
Cachexia
Cachexia will be evaluated with weight (in kilograms)
Time frame: Cachexia will be assessed up to 3 years after the last day of radiotherapy.
Plan to share: No
Ran from Mar 2019 to primary completion in Mar 2021, 23 months.
Completion moved once since we started tracking on Sep 25, 2026: May 2026 → Jun 2024, on Nov 9, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
A change in patient care. Competing trials with the expansion of immunotherapies, Difficulties in manufacturing and obtaining products for double-blind studies. The health situation, with an temporary halt due to COVID-19.
A change in patient care. Competing trials with the expansion of immunotherapies, Difficulties in manufacturing and obtaining products for double-blind studies. The health situation, with an temporary halt due to COVID-19.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Squamous Cell Carcinoma of Head and Neck →
Institut du Cancer de Montpellier - Val d'Aurelle →